Skip to main content
Clinical Trials/JPRN-jRCTs031200436
JPRN-jRCTs031200436
Completed
Phase 2

A prospective multi-center open trial to evaluate the safety and efficacy of favipiravir and camostat mesilate in patients with COVID-19.

Yutaka Tokue0 sites12 target enrollmentMarch 23, 2021

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
COVID-19
Sponsor
Yutaka Tokue
Enrollment
12
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

It was a registration of a small number of cases and did not lead to a statistical examination.

Registry
who.int
Start Date
March 23, 2021
End Date
July 30, 2021
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Yutaka Tokue

Eligibility Criteria

Inclusion Criteria

  • 1\) SARS\-CoV\-2 test positive
  • 2\) diagnosed with COVID\-19
  • 3\) fever above 37\.5 degree Celsius, or pneumonia shadow on chest X\-ray or CT\-scan
  • 4\) hospital admission
  • 6\) patients who have given written consent to participate in the study

Exclusion Criteria

  • 1\) pregnancy
  • 2\) lactation
  • 3\) Women who are not able to give informed consent regarding contraception and using contraceptive divices from the initiation of favipiravir to 14 days after the end of its administration. Men or their partners who are not able to give informed consent regarding contraception and using contraceptive divices from the initiation of favipiravir to 10 days after the end of its administration.

Outcomes

Primary Outcomes

Not specified

Similar Trials